Compulsory Licensing High On China Health Regulator’s Policy Agenda
This article was originally published in PharmAsia News
Compulsory licensing, along with essential drugs and orphan diseases, tops the list of policy issues picked by the National Health Commission’s Drug Policy Bureau, underscoring the willingness and stepped up effort by the Chinese regulator to examine and tackle particularly thorny issues.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.